BC Platforms
BC Platforms is a technology company that specializes in providing a unique data and technology platform for life sciences and healthcare companies. Their Data Access Platform offers access to valuable real-world data (RWD), clinical, genomics, and omics data through a data-as-a-service model. This enables pharmaceutical companies to enhance various use cases within the research and development continuum, from early discovery to post-market processes. The company's technology platform also supports healthcare providers and life science companies in producing, managing, and analyzing complex genomic data as a clinical decision-support solution. BC Platforms' Data Partner Network covers over 22 million life-years of highly curated patient data from around the world, ensuring compatibility with relevant technical standards and compliance with local privacy laws.
2 past transactions
Medexprim
Acquisition in 2023
Medexprim is a technology company that facilitates collaboration between hospitals and pharmaceutical companies by providing a research data platform. This platform aggregates and shares imaging, clinical, biological, and genomic data, along with AI and medical device integration, to accelerate precision medicine. By doing so, Medexprim helps reduce time, cost, and risks associated with medical research and development.
4Pharma
Acquisition in 2023
4Pharma is a contract research organization (CRO) that specializes in providing medical research services to clients in the pharmaceutical, biotechnology, medical device, and food industries. The company possesses extensive expertise across a wide range of therapeutic areas, enabling it to offer tailored solutions in biostatistics, data management, medical writing, and information technology. By focusing on these key services, 4Pharma helps clients efficiently manage and deliver clinical trial data while ensuring cost-effectiveness.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.